GS71 Stock Overview
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£16.30 |
| 52 Week High | UK£21.57 |
| 52 Week Low | UK£15.70 |
| Beta | 0.33 |
| 11 Month Change | -10.19% |
| 3 Month Change | -11.53% |
| 1 Year Change | 2.40% |
| 33 Year Change | -30.64% |
| 5 Year Change | -34.39% |
| Change since IPO | -55.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| GS71 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -4.6% | -1.2% |
| 1Y | 2.4% | -19.2% | 9.0% |
Return vs Industry: GS71 exceeded the German Pharmaceuticals industry which returned -19.2% over the past year.
Return vs Market: GS71 underperformed the German Market which returned 9% over the past year.
Price Volatility
| GS71 volatility | |
|---|---|
| GS71 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GS71 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GS71's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GS71 fundamental statistics | |
|---|---|
| Market cap | €66.86b |
| Earnings (TTM) | €3.02b |
| Revenue (TTM) | €37.67b |
22.1x
P/E Ratio1.8x
P/S RatioIs GS71 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GS71 income statement (TTM) | |
|---|---|
| Revenue | UK£31.31b |
| Cost of Revenue | UK£8.65b |
| Gross Profit | UK£22.67b |
| Other Expenses | UK£20.15b |
| Earnings | UK£2.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 72.39% |
| Net Profit Margin | 8.02% |
| Debt/Equity Ratio | 119.4% |
How did GS71 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield99%
Payout RatioDoes GS71 pay a reliable dividends?
See GS71 dividend history and benchmarks| GSK dividend dates | |
|---|---|
| Ex Dividend Date | Nov 14 2024 |
| Dividend Pay Date | Jan 09 2025 |
| Days until Ex dividend | 0 days |
| Days until Dividend pay date | 56 days |
Does GS71 pay a reliable dividends?
See GS71 dividend history and benchmarks